PMP22 and early-onset autosomal dominant Alzheimer disease: The anti-ferroptotic drugs J147 and CMS121 show promise for treating Alzheimer’s disease, and might be re-purposed for PNS disorders, including CMT1A [25,26,27,28,29,30,31].